Skip to content

Phosphorous Magnetic Resonance Spectroscopy of Heart

31P Magnetic Resonance Spectroscopy of Heart

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01110395
Enrollment
15
Registered
2010-04-26
Start date
2009-06-30
Completion date
2011-06-30
Last updated
2020-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Left Ventricular Dysfunction

Brief summary

Heart needs constant supply of energy to continue working. Phosphorus magnetic resonance spectroscopy allows us to measure energy produced in the heart. The purpose of this study is to determine if the energy production is reduced in failing heart.

Detailed description

We will use non-invasive phosphorus magnetic resonance spectroscopy technique to measure creatine kinase (CK) flux in failing heart. The studies will be done on Siemens 3.0T human system. We will recruit subjects with LV dysfunction due to prior anterior wall myocardial infarction.

Interventions

DIAGNOSTIC_TESTMR Spectroscopy

MR spectroscopy of myocardial

Sponsors

Washington University School of Medicine
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Individuals with left ventricular dysfunction

Exclusion criteria

* Age \< 18, pregnant, history of excessive alcohol use, or any condition (e.g. claustrophobia, a pacemaker) that would prevent him/her from completing the magnetic resonance spectroscopy study

Design outcomes

Primary

MeasureTime frame
An MR Spectroscopy Showing Signal to Noise Ratio to Determine the Level of Heart Failure1-2 days

Countries

United States

Participant flow

Recruitment details

Patients recruited from heart transplant clinic

Participants by arm

ArmCount
Heart Failure
Magnetic Resonance Spectroscopy
15
Total15

Baseline characteristics

CharacteristicHeart Failure
Age, Categorical
<=18 years
0 Participants
Age, Categorical
>=65 years
0 Participants
Age, Categorical
Between 18 and 65 years
15 Participants
Sex: Female, Male
Female
2 Participants
Sex: Female, Male
Male
13 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 15
other
Total, other adverse events
0 / 15
serious
Total, serious adverse events
0 / 15

Outcome results

Primary

An MR Spectroscopy Showing Signal to Noise Ratio to Determine the Level of Heart Failure

Time frame: 1-2 days

ArmMeasureValue (MEAN)Dispersion
MR Spectroscopy Post-Heart TransplantAn MR Spectroscopy Showing Signal to Noise Ratio to Determine the Level of Heart Failure7 RatioStandard Deviation 13.67
Comparison: We are unable to provide any further data that has been requested. We have supplied all the data that we can possibly provide because the PI has left the institution and we are unable to contact him. We have no other data.mean + SD
p-value: <0.05Mean + SD

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026